Terms: = Ovarian cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1
35 results:
1. FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Di Filippo G; Franchini E; Massari F; Mollica V; Tateo V; Bianchi FM; Colecchia M; Acosta AM; Fiorentino M
Histopathology; 2023 Sep; 83(3):465-476. PubMed ID: 37317674
[TBL] [Abstract] [Full Text] [Related]
2. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation.
Aird R; Wills J; Roby KF; Bénézech C; Stimson RH; Wabitsch M; Pollard JW; Finch A; Michailidou Z
Front Endocrinol (Lausanne); 2022; 13():989523. PubMed ID: 36329893
[TBL] [Abstract] [Full Text] [Related]
4. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract] [Full Text] [Related]
5. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract] [Full Text] [Related]
6. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract] [Full Text] [Related]
7. HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors.
Gallo A; Fankhauser C; Hermanns T; Beyer J; Christiansen A; Moch H; Bode PK
Mod Pathol; 2020 Nov; 33(11):2354-2360. PubMed ID: 32561848
[TBL] [Abstract] [Full Text] [Related]
8. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract] [Full Text] [Related]
9. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
[TBL] [Abstract] [Full Text] [Related]
10. [Pathologic features on gonadal changes of sexual developmental disorders in children].
Yi P; Niu HL; Gao Q; Wang FH; Jia W; Chen ZR; Xia JQ; Li LP; Cao Y; Zeng RX
Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):531-535. PubMed ID: 29996319
[No Abstract] [Full Text] [Related]
11. Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review.
Chao WT; Liu CH; Lai CR; Chen YJ; Chuang CM; Wang PH
J Ovarian Res; 2018 Jun; 11(1):52. PubMed ID: 29933751
[TBL] [Abstract] [Full Text] [Related]
12. Germ cell tumour growth patterns originating from clear cell carcinomas of the ovary and endometrium: a comparative immunohistochemical study favouring their origin from somatic stem cells.
Nogales FF; Prat J; Schuldt M; Cruz-Viruel N; Kaur B; D'Angelo E; Matias-Guiu X; Vidal A; McCluggage WG; Oosterhuis JW
Histopathology; 2018 Mar; 72(4):634-647. PubMed ID: 29106744
[TBL] [Abstract] [Full Text] [Related]
13. [cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract] [Full Text] [Related]
14. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract] [Full Text] [Related]
15. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract] [Full Text] [Related]
16. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.
Januchowski R; Zawierucha P; Ruciński M; Nowicki M; Zabel M
Biomed Res Int; 2014; 2014():365867. PubMed ID: 24804215
[TBL] [Abstract] [Full Text] [Related]
17. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract] [Full Text] [Related]
18. [The cancer specific antigen, glypican-3 (gpc3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract] [Full Text] [Related]
19. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract] [Full Text] [Related]
20. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract] [Full Text] [Related]
[Next]
